PMID

Data

Article Title

Organization

Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.

Berlex Biosciences

Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors.

Berlex Biosciences

Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.

Berlex Biosciences

Discovery of novel non-peptide CCR1 receptor antagonists.

Berlex Biosciences

Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).

Berlex Biosciences

Discovery of novel and potent aryl diamines as leukotriene A4 hydrolase inhibitors.

Berlex Biosciences

Synthesis of N-alkyl glycine amides as potent inhibitors of leukotriene A4 hydrolase.

Berlex Biosciences

1-(1,3-Benzodioxol-5-ylmethyl)-3-[4-(1H-imidazol-1-yl)phenoxy]-piperidine analogs as potent and selective inhibitors of nitric oxide formation.

Berlex Biosciences

The rational design of inhibitors of nitric oxide formation by inducible nitric oxide synthase.

Berlex Biosciences

Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors.

Berlex Biosciences

CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives.

Berlex Biosciences

3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).

Berlex Biosciences

CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives.

Berlex Biosciences

Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1).

Berlex Biosciences

Synthesis and biological evaluation of menthol-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1).

Berlex Biosciences

Benzimidazole-based fXa inhibitors with improved thrombin and trypsin selectivity.

Berlex Biosciences

Design and synthesis of aminophenol-based factor Xa inhibitors.

Berlex Biosciences

Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.

Berlex Biosciences

Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.

Berlex Biosciences

Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.

Berlex Biosciences

Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.

Berlex Biosciences

Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.

Berlex Biosciences

Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor XA inhibitors.

Berlex Biosciences

Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.

Berlex Biosciences

(Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa.

Berlex Biosciences

Benzimidazole derivatives as antihistamine agents

Faes Farma

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Viiv Healthcare UK (NO.5)

Nuclear receptor modulators

Abbvie

Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.

Agouron Pharmaceuticals

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

Pfizer